Article
Chemistry, Multidisciplinary
Ke Li, Kun Xu, Ye He, Yulu Yang, Meijun Tan, Yulan Mao, Yanan Zou, Qian Feng, Zhong Luo, Kaiyong Cai
Summary: In this study, a nanoreactor Cu2-xSe was developed to alleviate the intracellular hypoxia environment and enhance the catalytic and cell death-inducing activities. The nanoreactors were surface functionalized with PEG polymer and folic acid molecules to ensure in vivo blood circulation and tumor-specific uptake. The functionalized self-supplying nanoreactors demonstrated the ability to generate O2 and consume intracellular GSH through the interconversion of Cu elements, impairing the GPX4/GSH pathway and HIF-1α protein expression. Furthermore, by alleviating the intracellular hypoxia environment, the nanoreactors affected the phenotype polarization of TAMs and increased the content of IFNγ secreted by CD8+ T cells, promoting cell death induced by Erastin-loaded nanoreactors. This combined therapeutic strategy provides a potential approach for clinical application.
Editorial Material
Oncology
Priyanka Sharma
Summary: Pathologic response is an important tool for optimizing the escalation and deescalation of adjuvant treatment. Neoadjuvant carboplatin-taxane combination shows promise as a chemotherapy deescalation strategy for triple-negative breast cancer. However, several key points, including trial design/patient selection, response biomarkers, role of immunotherapy, and patient advocate input, need to be carefully considered for the advancement of neoadjuvant chemotherapy deescalation investigations.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Lili Yang, Yuya Haga, Akihide Nishimura, Yuki Tsujii, Suzuno Tanahashi, Hirofumi Tsujino, Kazuma Higashisaka, Yasuo Tsutsumi
Summary: Among TNBC subtypes, the BL2 subtype has the lowest survival rate and highest risk of metastasis after chemotherapy treatment. Alpha B-crystallin (CRYAB) is highly expressed in BL2 subtypes and is associated with brain metastasis in TNBC patients. We hypothesized that alpha B-crystallin is associated with increased cell motility in the BL2 subtype after chemotherapy.
SCIENTIFIC REPORTS
(2023)
Review
Nanoscience & Nanotechnology
Siyan Liu, Jing Li, Lin Gu, Kunzhe Wu, Hua Xing
Summary: Chemoimmunotherapy shows promise for treating TNBC, but challenges remain in improving efficacy and reducing side effects.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Article
Engineering, Biomedical
Tian-Yan Han, Meng-Lei Huan, Zedong Cai, Wei He, Si-Yuan Zhou, Bang-Le Zhang
Summary: This study develops a novel nonviral vector PSM that can simultaneously target cellular uptake pathways and intracellular responsive release for miR-34a, achieving effective treatment for TNBC. This strategy provides a promising approach for gene therapy.
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Biochemistry & Molecular Biology
Ji-Yeon Kim, Sabin Park, Eun Yoon Cho, Jeong Eon Lee, Hae Hyun Jung, Byung Joo Chae, Seok Won Kim, Seok Jin Nam, Soo Youn Cho, Yeon Hee Park, Jin Seok Ahn, Semin Lee, Young-Hyuck Im
Summary: This study compared the genetic characteristics of apocrine carcinoma, a rare subtype of breast cancer, with triple negative breast cancer (TNBC) with low Ki-67 expression (LK-TNBC). The most frequently mutated driver gene in apocrine carcinoma was TP53, followed by PIK3CA, ZNF717, and PIK3R1. Apocrine carcinoma exhibited defective DNA mismatch repair and APOBEC activity-associated mutational signatures, and had better five-year disease-free survival and overall survival rates compared to LK-TNBC.
EXPERIMENTAL AND MOLECULAR MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Xupeng Bai, Jie Ni, Julia Beretov, Valerie C. Wasinger, Shanping Wang, Ying Zhu, Peter Graham, Yong Li
Summary: Triple-negative breast cancer (TNBC) is the most aggressive subtype, and radiotherapy is an effective treatment option. However, acquired radioresistance is a major challenge. The integrated stress response (ISR) pathway is found to be highly activated in radioresistant TNBC cells, with the eIF2 alpha /ATF4 axis proposed as a potential therapeutic target.
Article
Medicine, General & Internal
P. Schmid, J. Cortes, R. Dent, L. Pusztai, H. McArthur, S. Kummel, J. Bergh, C. Denkert, Y. H. Park, R. Hui, N. Harbeck, M. Takahashi, M. Untch, P. A. Fasching, F. Cardoso, J. Andersen, D. Patt, M. Danso, M. Ferreira, M-A Mouret-Reynier, S-A Im, J-H Ahn, M. Gion, S. Baron-Hay, J-F Boileau, Y. Ding, K. Tryfonidis, G. Aktan, V Karantza, J. O'Shaughnessy
Summary: The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery significantly prolonged event-free survival in patients with early triple-negative breast cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Chemistry, Medicinal
Masayori Hagimori, Naoya Kato, Akira Orimoto, Tadaharu Suga, Shigeru Kawakami
Summary: Triple-negative breast cancer (TNBC) is a highly malignant tumor that lacks expression of ER, PR, and HER-2. MUC16, an overexpressed glycoprotein in breast cancer, has been targeted for developing novel strategies for TNBC treatment. In this study, a MUC16 targeted peptide (EVQ)-grafted lipid derivative (EVQ-(SG)(5)-lipid) was synthesized and used to prepare EVQ-(SG)(5)/PEGylated liposomes. The association between EVQ-(SG)(5)/PEGylated liposomes and TNBC cell lines was investigated, along with the intracellular distribution and cellular uptake pathway of these liposomes as drug delivery carriers for TNBC.
JOURNAL OF PHARMACEUTICAL SCIENCES
(2023)
Article
Cell Biology
Juliana Haydee Enrique Steinberg, Fabiana Alejandra Rossi, Roberto Magliozzi, Laurensia Yuniati, Matteo Santucci, Mario Rossi, Daniele Guardavaccaro, Angela Lauriola
Summary: The research demonstrates that SHARP1 functions as a suppressor of metastasis in TNBC. It inhibits the invasive phenotype of TNBC by blocking hypoxia-inducible factors. Additionally, targeting the beta TrCP-dependent degradation of SHARP1 shows potential as a therapeutic strategy in TNBC.
CELL DEATH & DISEASE
(2023)
Review
Pharmacology & Pharmacy
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala
Summary: Triple negative breast cancer (TNBC) is a subtype of breast cancer that lacks estrogen receptors, progesterone receptors, and human epidermal growth factor receptors. The survival rate for TNBC is generally lower than other subtypes. Chemotherapy is the most common treatment option, but resistance to drugs and off-target toxicity pose challenges. Researchers, clinicians, and pharmaceutical companies must collaborate to develop effective treatments for TNBC. Nanotechnology has shown promise as a potential solution for improving TNBC treatment.
Article
Cell Biology
Duo Zhang, Albert M. Li, Guanghui Hu, Menggui Huang, Fan Yang, Lin Zhang, Kathryn E. Wellen, Xiaowei Xu, Crystal S. Conn, Wei Zou, Mark Kahn, Seth D. Rhoades, Aalim M. Weljie, Serge Y. Fuchs, Nduka Amankulor, Daniel Yoshor, Jiangbin Ye, Constantinos Koumenis, Yanqing Gong, Yi Fan
Summary: Phosphoglycerate dehydrogenase (PHGDH)-mediated endothelial cell metabolism contributes to the formation of a hypoxic and immune-hostile vascular microenvironment, leading to glioblastoma resistance to CAR-T cell immunotherapy. Reprogramming endothelial metabolism by targeting PHGDH may improve T cell-based immunotherapy.
Review
Engineering, Biomedical
Pallabita Chowdhury, Upasana Ghosh, Kamalika Samanta, Meena Jaggi, Subhash C. Chauhan, Murali M. Yallapu
Summary: Management of aggressive breast cancer, particularly TNBC, remains challenging despite advances in treatment. New therapies like atezolizumab, olaparib, and sacituzumab show limited survival benefits. Current research aims to improve treatment strategies by enhancing bioavailability, targetability, and reducing toxicity for better therapeutic outcomes.
BIOACTIVE MATERIALS
(2021)
Article
Oncology
Marine Lemesle, Marine Geoffroy, Fabien Alpy, Catherine-Laure Tomasetto, Sandra Kuntz, Isabelle Grillier-Vuissoz
Summary: This study investigated the role of CLDN1 in triple-negative breast cancer (TNBC) and found that CLDN1 can increase the sensitivity of TNBC cells to chemotherapy drugs. The findings support the use of CLDN1 as a predictive marker for chemotherapy response in TNBC.
Article
Nanoscience & Nanotechnology
Zhongjie Wang, Yanru Qin, Xueyuan Wang, Tianyu Zhang, Yixue Hu, Dongna Wang, Liefeng Zhang, Yongqiang Zhu
Summary: This study aimed to develop a targeted delivery system for Lonidamine (LND) using poly(lactic-co-glycolic acid) (PLGA) nanoparticles wrapped with mitochondria-targeting and tumor-targeting ligands. Encapsulation of LND in the nanoparticles improved its solubility and specifically targeted mitochondria, leading to effective treatment against triple negative breast cancer. The nanoparticles displayed excellent anticancer activity by inducing mitochondrial damage and apoptosis in tumor cells, while effectively reducing LND toxicity.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)